$HEB News Wednesday's biggest gaining and declining

New Post Public Reply Private Reply Replies (0) Message Board

Jul 13, 2014 at 1:02 PM

$HEB News

Wednesday's biggest gaining and declining stocks 6:03 p.m. Dec. 2, 2009 - MarketWatch
Dyax, Santarus, CytRx soar; Hemispherx craters 12:38 p.m. Dec. 2, 2009 - Val Brickates Kennedy
Stocks in focus for Wednesday 7:47 p.m. Dec. 1, 2009 - MarketWatch
Ford tips higher, Santarus surges in late session 7:37 p.m. Dec. 1, 2009 - Laura Mandaro
Hemispherx Biopharma shares sink 44% after hours 6:29 p.m. Dec. 1, 2009 - Laura Mandaro
Oops: I have to eat crow over these stupid picks 9:55 a.m. June 19, 2009 - Chuck Jaffe
Vaccine makers get boost from flu scare 1:20 p.m. May 21, 2009 - Val Brickates Kennedy
Hemispherx leads drug stocks lower 1:29 p.m. May 19, 2009 - Val Brickates Kennedy
Dr. Reddy's, Hemispherx lead drug stocks 1:24 p.m. May 18, 2009 - Val Brickates Kennedy
Pigs will get slaughtered on swine-flu stocks 6:27 p.m. April 30, 2009 - Chuck Jaffe
Shares of antiviral drugmakers rocket on flu news 1:54 p.m. April 27, 2009 - Val Brickates Kennedy
Niche antiviral drugmakers rocket on flu news 10:08 a.m. April 27, 2009 - Val Brickates Kennedy
Hemispherx started at mkt outperform: Boenning & Scattergood 3:47 p.m. Dec. 4, 2006 - Tomi Kilgore
Tuesday's biggest stock gainers and decliners 6:21 p.m. Aug. 29, 2006 - Michael Baron
Short sellers dwindle as multiple forces aim to thwart strategy 11:51 a.m. June 14, 2006 - Alistair Barr
Highlights of rising and falling U.S. stocks 4:58 p.m. May 24, 2006 - MarketWatch
Bird-flu concerns knock airlines, Asian currencies 4:52 p.m. May 24, 2006 - Steve Goldstein
Drug stocks mixed, bird-flu drugmakers rally 4:51 p.m. May 24, 2006 - Val Brickates Kennedy
Hemisherx BioPharma up 10% at $2.95 9:39 a.m. May 24, 2006 - Tomi Kilgore
Drug stocks end mixed; Serono dives on sale plan 4:40 p.m. April 10, 2006 - Val Brickates Kennedy

10-K: HEMISPHERX BIOPHARMA INC 4:06 p.m. March 14, 2014 - Edgar Online - (EDG = 10Q, 10K)
10-Q: HEMISPHERX BIOPHARMA INC 5:06 p.m. Nov. 8, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: HEMISPHERX BIOPHARMA INC 4:15 p.m. Aug. 9, 2013 - Edgar Online - (EDG = 10Q, 10K)
Biotechs Ramping Up On China's Avian Flu Outbreak 2:42 a.m. April 8, 2013 - Seeking Alpha
Biotech Movers: A Doubler for Opexa 3:30 a.m. Feb. 11, 2013 - InvestorPlace.com
2 Biotech Stocks That Could Be Prime Candidates For The Short Seller 12:18 p.m. Dec. 21, 2012 - Seeking Alpha
Panel Rejects Drug for Chronic Fatigue Syndrome 7:52 p.m. Dec. 20, 2012 - The Wall Street Journal Interactive Edition
Amgen Licenses ImmunoGen Tech, Hemispherx Drug Questioned by FDA: Healthcare Business Recap 4:25 p.m. Dec. 19, 2012 - Wall St. Cheat Sheet
Stock Watch Wednesday, 19 December 10:24 a.m. Dec. 19, 2012 - Seeking Alpha
Hemispherx Faces FDA Day 7:51 a.m. Dec. 19, 2012 - Seeking Alpha
FDA Questions Hemispherx's Fatigue Drug 6:12 p.m. Dec. 18, 2012 - The Wall Street Journal Interactive Edition
Strong Small Cap Biopharma Catalyst Trades And Investments For Consideration 8:55 a.m. Dec. 18, 2012 - Seeking Alpha
Hemispherx's Ampligen Is Unlikely To Receive FDA Approval 6:46 a.m. Dec. 18, 2012 - Seeking Alpha
Potential Drug for Fatigue to Get New Review 11:21 p.m. Dec. 16, 2012 - The Wall Street Journal Interactive Edition
Ampligen: The Political Calculus Has Changed 6:37 a.m. Dec. 12, 2012 - Seeking Alpha
Tuesday's Small-Cap Biopharma Catalyst Trade List 9:45 a.m. Dec. 11, 2012 - Seeking Alpha
Hemispherx's Ampligen For The Treatment Of Chronic Fatigue Syndrome: A Regulatory Conundrum 5:52 a.m. Dec. 9, 2012 - Seeking Alpha
Hemispherx Biopharma: A Voice Of Reason Amid The Din 8:34 a.m. Dec. 4, 2012 - Seeking Alpha
3 Stocks With High Alphas: Acadia, Hemispherx, And Vringo 10:50 a.m. Nov. 8, 2012 - Seeking Alpha
Savient Pharmaceuticals May Continue To Run Higher 1:10 p.m. Oct. 9, 2012 - Seeking Alpha

Hemispherx Biopharma and Bioclones Join Forces in Effort to Eradicate HIV/AIDS Virus Based on Recent Clinical Insights of Wistar Institute, University of Pennsylvania 8:31 a.m. July 8, 2014 - GlobeNewswire
Hemispherx Biopharma to Present During the 2014 BIO International Convention June 26 8:30 a.m. June 25, 2014 - GlobeNewswire
Hemispherx Announces New Publication With Potential Insight Into High Mortality Rate in Middle Eastern Respiratory Syndrome (MERS) 8:31 a.m. June 16, 2014 - GlobeNewswire
Hemispherx Announces That the University of Texas Medical Branch Confirms Activity of Alferon(R) N Against MERS (Middle East Respiratory Syndrome) Virus 1:08 p.m. June 3, 2014 - GlobeNewswire
Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen(R) Formulations 9:28 a.m. May 27, 2014 - GlobeNewswire
Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets 8:31 a.m. May 21, 2014 - GlobeNewswire
Hemispherx Biopharma Formally Collaborates With the Swiss Department of Defense, Civil Protection and Sports to Study Alferon(R) Against Tamiflu Resistant Influenza Virus Strains 8:31 a.m. May 14, 2014 - GlobeNewswire
Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2014 4:16 p.m. May 9, 2014 - GlobeNewswire
Technical Recap on Biotech Equities -- Research on Hemispherx Biopharma, Orexigen Therapeutics, Dynavax Technologies, and Synergy Pharma 2:30 p.m. May 8, 2014 - PR Newswire - PRF
Alferon(R) N Effective Against MERS (Middle East Respiratory Syndrome) Virus In-Vitro 8:32 a.m. May 5, 2014 - GlobeNewswire
Coverage of Biotech Equities -- Research on Arena Pharma, Celgene, PDL BioPharma, and Hemispherx Biopharma 1:20 p.m. April 8, 2014 - PR Newswire - PRF
Hemispherx Biopharma Announces New Publication Enlarges the Understanding of Ampligen(R) Safety Profile Across Diverse Animal Species and Focuses on the Unique TLR-3 Receptor/Ampligen(R) Interaction 8:31 a.m. April 8, 2014 - GlobeNewswire
Hemispherx Biopharma, Inc. Presented Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference 8:33 a.m. March 24, 2014 - GlobeNewswire
Momentum Indicators for Health Care Equities -- Research on Arena Pharma, Hemispherx Biopharma, PDL BioPharma and Celgene 8:16 a.m. March 20, 2014 - PR Newswire - PRF
Hemispherx Biopharma, Inc. to Present Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference 8:30 a.m. March 19, 2014 - GlobeNewswire
Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2013 8:30 a.m. March 14, 2014 - GlobeNewswire
Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen(R) to Treat Chronic Fatigue Syndrome (CFS) in Three Additional Latin America Countries 11:01 a.m. March 10, 2014 - GlobeNewswire
Hemispherx Biopharma Wins Federal Lawsuit Regarding Investment Banking Fees 8:30 a.m. March 10, 2014 - GlobeNewswire
Hemispherx Biopharma Publishes Full National Press Club Presentation on Corporate Website 9:30 a.m. Feb. 24, 2014 - GlobeNewswire
Hemispherx Biopharma Summarizes Clinical Results Presented in Washington, DC on January 30, 2014 in Conjunction with the American Society for Microbiology (ASM) Biodefense Conference Aimed at Developing a Universal Influenza Vaccine to Prevent Pandemic Influenza Threat 11:48 p.m. Feb. 4, 2014 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BULL Faces Class Action After Regulatory Fines

Webull's Financial Quake Shakes Investors You don't expect to wake up to news of a stock in freefall, but here we are with Webull (NASDAQ:BULL) cratering after some rough compliance problems came to light. On November 5, 2026, Webull's stock tumbled nearly 11% thanks to FINRA slapping them with a $4.2 million fine for failing to keep their anti-money laundering (AML) and...

GTEC Faces Nasdaq Bid Price Compliance Challenge

Greenland Technologies in a Tight Spot Man, stocks can be as unpredictable as a cat on a hot tin roof, and Greenland Technologies Holding Corporation (Nasdaq: GTEC) just got a cold splash of reality from Nasdaq. On November 10, 2026, they were handed a Notification Letter that ain’t exactly a love note. Their shares slipped below the one-buck hurdle, and Nasdaq isn’t...

U-wifi Gains Charlie Vogt: Key Steps in 5G Expansion

Charlie Vogt Joins U-wifi: A Broadband Game Changer? There's a new player in town shaking things up, and he's no rookie. Charlie Vogt, five-time technology CEO and Managing Director at Bowen, is hopping onto U-wifi's board of directors. This isn't just about another corporate announcement; it's like adding a veteran quarterback to your expansion team. Vogt’s pedigree in...

Partner Joins Yardi ICN, Boosting Data Quality for Clients

Strategic Alliances in Real Estate Data When Partner Engineering and Science, Inc. says they're hooking up with the Yardi Independent Consultant Network (ICN), that's not just some boardroom handshake. It's a play that could shake up data services in the real estate game. Look, there's plenty of chatter about digitizing property management, but without killer data, those...

Choosing Screen-Free Outdoor Gifts: besrey's Top Picks

The Art of Choosing Outdoor Gifts for Kids Christmas time, my friends, isn't just about plastic gimmicks and gadgets vying for kids' attention. Nope, it's about making thoughtful decisions that blend discovery, movement, and a little peace of mind for parents. This time around, besrey's got the scoop on screen-free gifts that might just do the trick—helping kids explore...

SAHZU Hospital Earns GHA Distinction for Travel Care

A New Benchmark in International Patient Experience When a hospital sets the standard for treating foreign patients like family, it deserves recognition. That's exactly what's happened at The Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU), which just snagged an impressive accolade from Global Healthcare Accreditation (GHA). For anyone keeping...

Cemig and Huawei's Bold Network Leap: Power Up

By Ryan Hughes Updated Nov 13, 2026 Category News Views 100

Taking the Leap in Brazil's Power Grid In Brazil, energy distribution's a whole different beast, and boy, is it complicated! Cemig found out the hard way that relying on public networks was a risky bet. Consistently bad. With a measly 50% coverage in Brazil's vast lands, you're looking at a communications nightmare, especially in the back of beyond where grid faults could...

Revolutionary Sports Ball Backpack: A Game Changer?

Backpacks Reinvented by a Clever Mom Ever been caught in the whirlwind of juggling kids, sports gear, and school supplies? Well, one stay-at-home mom from Poway, California found herself in just such a predicament. She turned this everyday chaos into a creative solution by designing a unique Sports Ball Backpack. The idea came to her while managing a toddler, a newborn,...

DEEPBLUE's Panelized Systems Target Low-Rise Markets

Changing the Game in Low-Rise Construction Been around the block a few times and seen all sorts of hype in this industry, but what DEEPBLUE SMARTHOUSE is pushing sounds more like evolution than revolution for low-rise builds. They're leaning into this panelized building system like a boxer on the ropes—that's their strategy to keep things steady and predictable. The...

DraftKings Shares Tumble, Investors Grapple with Losses

DraftKings' Bold Moves Hit Investor Pockets Hard It ain't every day you see a company gamble nearly $700 million and come out with egg on its face. Yet, that's what DraftKings (NASDAQ: DKNG) seems to have done, and now it's shareholders who might be left holding the bag. On November 6, 2026, when DraftKings admitted it was doubling down on its Predictions business...